muscle stem cells fused into multinucleated myotubes
© Spuler Lab, MDC Berlin

Technology & Licensing

Our technology offers

The Max Delbrück Center has a unique record of discovery and innovation leading to a diverse technology portfolio.

To find solutions for your business and technology needs, have a look at our technology offers on the website of our commercialization partner Ascenion. 

We also encourage you to contact the Technology Transfer Office for more information about current technology development at the Max Delbrück Center and the researchers behind them.

Intellectual property & patents

The Max Delbrück Center holds patents for technologies in 86 areas (including products and applications), with a total of 571 successful patents worldwide.

About the header image

mRNA introduced the gene editor CRISPR-Cas9 into human muscle stem cells

muscle stem cells fused into multinucleated myotubes

The researchers used mRNA to introduce the gene editor CRISPR-Cas9 into human muscle stem cells. These cells fused into multinucleated myotubes following mRNA-mediated CRISPR-Cas9 gene editing. A myosin heavy chain is seen in green and the nuclei in blue.

© Spuler Lab, MDC Berlin

Further information 

Related news & events

Gaetano Gargiulo

Gaetano Gargiulo.

© David Ausserhofer, MDC
Press Release No. 2

Third ERC Grant for Gaetano Gargiulo

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.
Radoslaw Wesolowski, Michael Bader and Dr. Edgar Specker

Radoslaw Wesolowski (left), Michael Bader (center) and Dr. Edgar Specker have teamed up to develop a potential therapeutic agent that influences serotonin levels.

© Peter Himsel, Campus Berlin-Buch GmbH
Press Release No. 54

New agent regulates serotonin production

Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market.
Group picture with Holger Gerhardt, Heike Graßmann, Kai Wegner, Katja Simon, Christoph Diebolder

f.l.t.r.: Deputy Scientific Director Holger Gerhardt, Administrative Director Heike Graßmann, Governing Mayor Kai Wegner, Group Leader Katja Simon and Technology Platform Leader Christoph Diebolder

© Felix Petermann, Max Delbrück Center
Institute & Campus

With passion and dedication in Berlin-Buch

An afternoon marked by innovation: Berlin's Mayor, Kai Wegner, visited the Max Delbrück Center on October 11, 2023, and subsequently inaugurated the BerlinBioCube innovation center on the Buch research campus. The BioCube, in close proximity, provides state-of-the-art laboratories and offices for life science startups and spin-offs, including those from the Max Delbrück Center.
Life Science Gründerzentrum BerlinBioCube

Life Science Gründerzentrum BerlinBioCube

© Peter Himsel / Campus Berlin-Buch GmbH
Institute & Campus

Boost for Berlin’s biotech sector

Campus Berlin-Buch has a new incubator for life science start-ups: 8,000 square meters of state-of-the-art laboratory and office space have been built on the Science and Technology Campus. The BerlinBioCube was ceremonially opened on October 11, 2023 in the presence of the Governing Mayor.